TY - JOUR
T1 - Understanding the key to targeting the IGF axis in cancer
T2 - A biomarker assessment
AU - Lodhia, Kunal
AU - Tienchaiananda, Piyawan
AU - Haluska, Paul
N1 - Publisher Copyright:
© 2015 Lodhia, Tienchaiananda and Haluska.
PY - 2015
Y1 - 2015
N2 - Type 1 insulin like growth factor receptor (IGF-1R) targeted therapies showed compelling pre-clinical evidence; however, to date, this failed to translate to patient benefit in Phase 2/3 trails in unselected patients. This was further complicated by the toxicity, including hyperglycemia, which largely results from the overlap between IGF and insulin signaling systems and associated feedback mechanisms. This has halted the clinical development of inhibitors targeting IGF signaling, which has limited the availability of biopsy samples for correlative studies to understand biomarkers of response. Indeed, a major factor contributing to lack of clinical benefit of IGF targeting agents has been difficulty in identifying patients with tumors driven by IGF signaling due the lack of predictive biomarkers. In this review we will describe the IGF system, rationale for targeting IGF signaling, the potential liabilities of targeting strategies and potential biomarkers that may improve success.
AB - Type 1 insulin like growth factor receptor (IGF-1R) targeted therapies showed compelling pre-clinical evidence; however, to date, this failed to translate to patient benefit in Phase 2/3 trails in unselected patients. This was further complicated by the toxicity, including hyperglycemia, which largely results from the overlap between IGF and insulin signaling systems and associated feedback mechanisms. This has halted the clinical development of inhibitors targeting IGF signaling, which has limited the availability of biopsy samples for correlative studies to understand biomarkers of response. Indeed, a major factor contributing to lack of clinical benefit of IGF targeting agents has been difficulty in identifying patients with tumors driven by IGF signaling due the lack of predictive biomarkers. In this review we will describe the IGF system, rationale for targeting IGF signaling, the potential liabilities of targeting strategies and potential biomarkers that may improve success.
KW - Biomarker discovery
KW - Endocrine system diseases
KW - IGF binding proteins
KW - IGF system and signaling
KW - Insulin receptor
KW - Insulin receptor substrate proteins
KW - Insulin-like growth factor receptor
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=84934272931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934272931&partnerID=8YFLogxK
U2 - 10.3389/fonc.2015.00142
DO - 10.3389/fonc.2015.00142
M3 - Review article
AN - SCOPUS:84934272931
SN - 2234-943X
VL - 5
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - JUN
M1 - 142
ER -